Stimuli-responsive flexible Lewis pair-modified nanoparticles for fluorescence imaging

Lewis Pair-Functionalized Pt(II) Complexes with Tunable Emission Color and Triplet-State Properties

Two emissive Pt(II) complexes containing dynamic "flexible" Lewis pair (FlexLP) ligands are reported. The FlexLP ligand encompasses a diphenylphosphine oxide Lewis base and a dimesitylborane Lewis acid attached to a bithiophene scaffold, which can switch between an open unbound Lewis pair and a bound P-O-B Lewis adduct depending on the hydrogen bond-donating (HBD) strength of the solvent. [Pt(FlexLP)₂] contains two FlexLP ligands, and [Pt(FlexLP)(Py)] contains one FlexLP ligand and one pyrene ligand. UV-vis absorption and fluorescence studies demonstrate that the FlexLP ligands switch between the open Lewis pair and the closed Lewis adduct in MeOH, a strong HBD solvent, and acetone, a weak HBD solvent, respectively, and exhibit tunable emission color depending on the acetone/MeOH solvent ratio. Transient absorption spectroscopy reveals a large difference in the triplet-state lifetime depending on the conformation of the FlexLP ligands for both complexes. In the closed form, the triplet-state lifetimes of the two complexes are over an order of magnitude longer compared to that of the complexes in the open conformation. Calculations of optimized geometries suggest that this difference in triplet-state lifetime is due to a difference in the thiophene-thiophene torsion angle between the two conformations.

Current Stimuli-Responsive Mesoporous Silica Nanoparticles for Cancer Therapy

With increasing incidence and mortality rates, cancer remains one of the most devastating global non-communicable diseases. Restricted dosages and decreased bioavailability, often results in lower therapeutic outcomes, triggering the development of resistance to conventionally used drug/gene therapeutics. The development of novel therapeutic strategies using multimodal nanotechnology to enhance specificity, increase bioavailability and biostability of therapeutics with favorable outcomes is critical. Gated vectors that respond to endogenous or exogenous stimuli, and promote targeted tumor delivery without prematurely cargo loss are ideal. Mesoporous silica nanoparticles (MSNs) are effective delivery systems for a variety of therapeutic agents in cancer therapy. MSNs possess a rigid framework and large surface area that can incorporate supramolecular constructs and varying metal species that allow for stimuli-responsive controlled release functions. Its high interior loading capacity can incorporate combination drug/gene therapeutic agents, conferring increased bioavailability and biostability of the therapeutic cargo. Significant advances in the engineering of MSNs structural and physiochemical characteristics have since seen the development of nanodevices with promising in vivo potential. In this review, current trends of multimodal MSNs being developed and their use in stimuli-responsive passive and active targeting in cancer therapy will be discussed, focusing on light, redox, pH, and temperature stimuli.